Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables
Andrew W Roberts, Shuo Ma, Thomas J Kipps, Steven E Coutre, Matthew S Davids, Barbara Eichhorst, Michael Hallek, John C Byrd, Kathryn Humphrey, Lang Zhou, Brenda Chyla, Jacqueline Nielsen, Jalaja Potluri, Su Young Kim, Maria Verdugo, Stephan Stilgenbauer, William G Wierda, John F Seymour
Blood | AMER SOC HEMATOLOGY | Published : 2019
Awarded by Australian NHMRC
Awarded by DFG
AbbVie and Genentech provided financial support for the studies (NCT01328626, NCT01889186, NCT01682616, and NCT02141282) and participated in the design, study conduct, analysis and interpretation of data, as well as the writing, review, and approval of the publication. Investigators also received support from the Australian NHMRC (1079560, 1113577) and Leukemia and Lymphoma Society (A.W.R.), DFG (SFB1074 projects B1 and B2; S.S.), and EU (TRANSCAN FIRECLL; S.S.). Financial support was also received from AbbVie, Inc. and Genentech Inc.